{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T17:41:51Z","timestamp":1755798111153,"version":"3.44.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,18]]},"DOI":"10.7759\/cureus.90433","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T02:33:03Z","timestamp":1755570783000},"source":"Crossref","is-referenced-by-count":0,"title":["Anti-Melanoma Differentiation-Associated Gene 5 Dermatomyositis With Rapidly Progressive Interstitial Lung Disease Complicated by Pneumothorax, Pneumomediastinum, and Subcutaneous Emphysema: Clinical Course Compared With Reported Cases Worldwide"],"prefix":"10.7759","author":[{"given":"Reuben P","family":"Kumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinay K","family":"Thallapally","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meghana","family":"Kesireddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sreekant","family":"Avula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.06.1309","article-title":"Dermatomyositis: clinical features and pathogenesis","volume":"82","author":"DeWane ME","year":"2020","unstructured":"DeWane ME, Waldman R, Lu J. Dermatomyositis: clinical features and pathogenesis. J Am Acad Dermatol. 2020, 82:267-81. 10.1016\/j.jaad.2019.06.1309","journal-title":"J Am Acad Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-021-04819-1","article-title":"Understanding and managing anti-MDA 5 dermatomyositis, including potential COVID-19 mimicry","volume":"41","author":"Mehta P","year":"2021","unstructured":"Mehta P, Machado PM, Gupta L. Understanding and managing anti-MDA 5 dermatomyositis, including potential COVID-19 mimicry. Rheumatol Int. 2021, 41:1021-36. 10.1007\/s00296-021-04819-1","journal-title":"Rheumatol Int"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-020-08822-5","article-title":"Interstitial lung disease in anti-MDA5 positive dermatomyositis","volume":"60","author":"Wu W","year":"2021","unstructured":"Wu W, Guo L, Fu Y, et al.. Interstitial lung disease in anti-MDA5 positive dermatomyositis. Clin Rev Allergy Immunol. 2021, 60:293-304. 10.1007\/s12016-020-08822-5","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.151959","article-title":"Management of MDA-5 antibody positive clinically amyopathic dermatomyositis associated interstitial lung disease: a systematic review","volume":"53","author":"McPherson M","year":"2022","unstructured":"McPherson M, Economidou S, Liampas A, Zis P, Parperis K. Management of MDA-5 antibody positive clinically amyopathic dermatomyositis associated interstitial lung disease: a systematic review. Semin Arthritis Rheum. 2022, 53:151959. 10.1016\/j.semarthrit.2022.151959","journal-title":"Semin Arthritis Rheum"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.14740\/jmc3965","article-title":"Anti-MDA5 associated clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease","volume":"13","author":"Tavakolian K","year":"2022","unstructured":"Tavakolian K, Odak M, Mararenko A, Ilagan J, Douedi S, Khan T, Al Saoudi G. Anti-MDA5 associated clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease. J Med Cases. 2022, 13:374-9. 10.14740\/jmc3965","journal-title":"J Med Cases"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/g4l70r","article-title":"Anti-MDA5-positive dermatomyositis and remission in a single referral centre population","volume":"41","author":"Tiniakou E","year":"2023","unstructured":"Tiniakou E, Mecoli CA, Kelly W, et al.. Anti-MDA5-positive dermatomyositis and remission in a single referral centre population. Clin Exp Rheumatol. 2023, 41:309-15. 10.55563\/clinexprheumatol\/g4l70r","journal-title":"Clin Exp Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.09.016","article-title":"The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study","volume":"65","author":"Fiorentino D","year":"2011","unstructured":"Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol. 2011, 65:25-34. 10.1016\/j.jaad.2010.09.016","journal-title":"J Am Acad Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160682","article-title":"Antimelanoma differentiation-associated gene 5 antibody: expanding the clinical spectrum in North American patients with dermatomyositis","volume":"44","author":"Moghadam-Kia S","year":"2017","unstructured":"Moghadam-Kia S, Oddis CV, Sato S, Kuwana M, Aggarwal R. Antimelanoma differentiation-associated gene 5 antibody: expanding the clinical spectrum in North American patients with dermatomyositis. J Rheumatol. 2017, 44:319-25. 10.3899\/jrheum.160682","journal-title":"J Rheumatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.6892-20","article-title":"Predictive factors for pneumomediastinum during management of connective tissue disease-related interstitial lung disease: a retrospective study","volume":"60","author":"Okamoto S","year":"2021","unstructured":"Okamoto S, Tsuboi H, Noma H, et al.. Predictive factors for pneumomediastinum during management of connective tissue disease-related interstitial lung disease: a retrospective study. Intern Med. 2021, 60:2887-97. 10.2169\/internalmedicine.6892-20","journal-title":"Intern Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.5348\/101247Z01SL2021CR","article-title":"Pneumomediastinum: a severe complication of dermatomyositis","volume":"12","author":"Lee SZ","year":"2021","unstructured":"Lee SZ, Syed MT, Kumar P. Pneumomediastinum: a severe complication of dermatomyositis. Int J Case Rep Images. 2021, 12:10.5348\/101247Z01SL2021CR","journal-title":"Int J Case Rep Images"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/ard.45.9.780","article-title":"Spontaneous pneumomediastinum in adult dermatomyositis","volume":"45","author":"Bradley JD","year":"1986","unstructured":"Bradley JD. Spontaneous pneumomediastinum in adult dermatomyositis. Ann Rheum Dis. 1986, 45:780-2. 10.1136\/ard.45.9.780","journal-title":"Ann Rheum Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S389839","article-title":"Spontaneous pneumomediastinum and subcutaneous emphysema in dermatomyositis: a case series and literature review","volume":"16","author":"Subki AH","year":"2023","unstructured":"Subki AH, Almani IM, Albeity A, Aljabri BK, Alsolaimani R, Halabi H. Spontaneous pneumomediastinum and subcutaneous emphysema in dermatomyositis: a case series and literature review. J Inflamm Res. 2023, 16:1431-41. 10.2147\/JIR.S389839","journal-title":"J Inflamm Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-015-3001-3","article-title":"Clinical and serological features of patients with dermatomyositis complicated by spontaneous pneumomediastinum","volume":"35","author":"Ma X","year":"2016","unstructured":"Ma X, Chen Z, Hu W, Guo Z, Wang Y, Kuwana M, Sun L. Clinical and serological features of patients with dermatomyositis complicated by spontaneous pneumomediastinum. Clin Rheumatol. 2016, 35:489-93. 10.1007\/s10067-015-3001-3","journal-title":"Clin Rheumatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2020.03.007","article-title":"Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease","volume":"50","author":"Romero-Bueno F","year":"2020","unstructured":"Romero-Bueno F, Diaz Del Campo P, Trallero-Aragu\u00e1s E, et al.. Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease. Semin Arthritis Rheum. 2020, 50:776-90. 10.1016\/j.semarthrit.2020.03.007","journal-title":"Semin Arthritis Rheum"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.820163","article-title":"Rituximab in the treatment of interstitial lung diseases related to anti-melanoma differentiation-associated gene 5 dermatomyositis: a systematic review","volume":"12","author":"He C","year":"2021","unstructured":"He C, Li W, Xie Q, Yin G. Rituximab in the treatment of interstitial lung diseases related to anti-melanoma differentiation-associated gene 5 dermatomyositis: a systematic review. Front Immunol. 2021, 12:820163. 10.3389\/fimmu.2021.820163","journal-title":"Front Immunol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s40674-021-00186-x","article-title":"Pharmacologic treatment of anti-MDA5 rapidly progressive interstitial lung disease","volume":"7","author":"Selva-O'Callaghan A","year":"2021","unstructured":"Selva-O'Callaghan A, Romero-Bueno F, Trallero-Aragu\u00e1s E, Gil-Vila A, Ruiz-Rodr\u00edguez JC, S\u00e1nchez-Pernaute O, Pinal-Fern\u00e1ndez I. Pharmacologic treatment of anti-MDA5 rapidly progressive interstitial lung disease. Curr Treatm Opt Rheumatol. 2021, 7:319-33. 10.1007\/s40674-021-00186-x","journal-title":"Curr Treatm Opt Rheumatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awz293","article-title":"Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib","volume":"142","author":"Sabbagh S","year":"2019","unstructured":"Sabbagh S, Almeida de Jesus A, Hwang S, et al.. Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib. Brain. 2019, 142:e59. 10.1093\/brain\/awz293","journal-title":"Brain"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.773352","article-title":"Dermatomyositis with anti-MDA5 antibodies: bioclinical features, pathogenesis and emerging therapies","volume":"12","author":"Nombel A","year":"2021","unstructured":"Nombel A, Fabien N, Coutant F. Dermatomyositis with anti-MDA5 antibodies: bioclinical features, pathogenesis and emerging therapies. Front Immunol. 2021, 12:773352. 10.3389\/fimmu.2021.773352","journal-title":"Front Immunol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.14335","article-title":"JAK inhibitors in refractory dermatomyositis: a case series","volume":"65","author":"Corbella-Bagot L","year":"2024","unstructured":"Corbella-Bagot L, Bosch-Amate X, Gimeno-Ribes E, et al.. JAK inhibitors in refractory dermatomyositis: a case series. Australas J Dermatol. 2024, 65:588-92. 10.1111\/ajd.14335","journal-title":"Australas J Dermatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1382728","article-title":"Therapeutic efficacy and safety of JAK inhibitors in treating polymyositis\/dermatomyositis: a single-arm systemic meta-analysis","volume":"15","author":"Ma C","year":"2024","unstructured":"Ma C, Liu M, Cheng Y, Wang X, Zhao Y, Wang K, Wang W. Therapeutic efficacy and safety of JAK inhibitors in treating polymyositis\/dermatomyositis: a single-arm systemic meta-analysis. Front Immunol. 2024, 15:1382728. 10.3389\/fimmu.2024.1382728","journal-title":"Front Immunol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/hxin6o","article-title":"Use of Janus kinase inhibitors in dermatomyositis: a systematic literature review","volume":"41","author":"Paik JJ","year":"2023","unstructured":"Paik JJ, Lubin G, Gromatzky A, Mudd PN Jr, Ponda MP, Christopher-Stine L. Use of Janus kinase inhibitors in dermatomyositis: a systematic literature review. Clin Exp Rheumatol. 2023, 41:348-58. 10.55563\/clinexprheumatol\/hxin6o","journal-title":"Clin Exp Rheumatol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa123","article-title":"Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment","volume":"59","author":"Shirakashi M","year":"2020","unstructured":"Shirakashi M, Nakashima R, Tsuji H, et al.. Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment. Rheumatology (Oxford). 2020, 59:3284-92. 10.1093\/rheumatology\/keaa123","journal-title":"Rheumatology (Oxford)"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.rcreue.2018.04.001","article-title":"Spontaneous pneumomediastinum complicating interstitial lung disease, associated with clinically amyopathic dermatomyositis and positive anti-MDA5 antibodies","volume":"24","author":"Sifuentes-Giraldo WA","year":"2017","unstructured":"Sifuentes-Giraldo WA, Garc\u00eda-Villanueva MJ, Gorospe L. Spontaneous pneumomediastinum complicating interstitial lung disease, associated with clinically amyopathic dermatomyositis and positive anti-MDA5 antibodies. Rev Colomb Reumatol. 2017, 24:259-64. 10.1016\/j.rcreue.2018.04.001","journal-title":"Rev Colomb Reumatol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.5935\/MEDICALEXPRESS.2018.MO009","article-title":"Spontaneous pneumomediastinum in dermatomyositis: a case series and literature review","volume":"5","author":"Pallo PA","year":"2018","unstructured":"Pallo PA, Shinjo SK. Spontaneous pneumomediastinum in dermatomyositis: a case series and literature review. Med Express. 2018, 5:10.5935\/MEDICALEXPRESS.2018.MO009","journal-title":"Med Express"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-018-0622-8","article-title":"MDA-5 associated rapidly progressive interstitial lung disease with recurrent pneumothoraces: a case report","volume":"18","author":"Alqatari S","year":"2018","unstructured":"Alqatari S, Riddell P, Harney S, Henry M, Murphy G. MDA-5 associated rapidly progressive interstitial lung disease with recurrent pneumothoraces: a case report. BMC Pulm Med. 2018, 18:59. 10.1186\/s12890-018-0622-8","journal-title":"BMC Pulm Med"},{"key":"ref26","article-title":"MDA-5 positive dermatomyositis complicated by pneumomediastinum","volume":"197","author":"Farrell S","year":"2018","unstructured":"Farrell S, Huprikar N, Hiles P. MDA-5 positive dermatomyositis complicated by pneumomediastinum. Am J Respir Crit Care Med. 2018, 197:A1569.","journal-title":"Am J Respir Crit Care Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.5387\/fms.2018-01","article-title":"Anti-MDA5 antibody-positive hypomyopathic dermatomyositis complicated with pneumomediastinum","volume":"64","author":"Yashiro M","year":"2018","unstructured":"Yashiro M, Asano T, Sato S, Kobayashi H, Watanabe H, Miyata M, Migita K. Anti-MDA5 antibody-positive hypomyopathic dermatomyositis complicated with pneumomediastinum. Fukushima J Med Sci. 2018, 64:89-94. 10.5387\/fms.2018-01","journal-title":"Fukushima J Med Sci"},{"key":"ref28","article-title":"Rapidly progressive interstitial lung disease associated with amyopathic dermatomyositis","volume":"199","author":"Tandon VO","year":"2019","unstructured":"Tandon VO, Nadler E, Tandon A, Manek G, Grover P. Rapidly progressive interstitial lung disease associated with amyopathic dermatomyositis. Am J Respir Crit Care Med. 2019, 199:A1547.","journal-title":"Am J Respir Crit Care Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2020-235493","article-title":"Case of anti-MDA-5 positive dermatomyositis with rapidly progressive interstitial lung disease","volume":"13","author":"Fenando A","year":"2020","unstructured":"Fenando A, Firn K, Louissa S, Hussain A. Case of anti-MDA-5 positive dermatomyositis with rapidly progressive interstitial lung disease. BMJ Case Rep. 2020, 13:e235493. 10.1136\/bcr-2020-235493","journal-title":"BMJ Case Rep"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.08.1054","article-title":"Holy Macklin! Severe pneumomediastinum associated with anti-MDA-5 antibody dermatomyositis","volume":"158","author":"Hwang J","year":"2020","unstructured":"Hwang J, Achamallah N. Holy Macklin! Severe pneumomediastinum associated with anti-MDA-5 antibody dermatomyositis. Chest. 2020, 158:A1156. 10.1016\/j.chest.2020.08.1054","journal-title":"Chest"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21833","article-title":"Anti-MDA-5 antibody-positive clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease treated with therapeutic plasma exchange: a case series","volume":"36","author":"Saito T","year":"2021","unstructured":"Saito T, Mizobuchi M, Miwa Y, et al.. Anti-MDA-5 antibody-positive clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease treated with therapeutic plasma exchange: a case series. J Clin Apher. 2021, 36:196-205. 10.1002\/jca.21833","journal-title":"J Clin Apher"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-021-00595-1","article-title":"Adolescent-onset anti-MDA5 antibody-positive juvenile dermatomyositis with rapidly progressive interstitial lung disease and spontaneous pneumomediastinum: a case report and literature review","volume":"19","author":"Yeung TW","year":"2021","unstructured":"Yeung TW, Cheong KN, Lau YL, Tse KN. Adolescent-onset anti-MDA5 antibody-positive juvenile dermatomyositis with rapidly progressive interstitial lung disease and spontaneous pneumomediastinum: a case report and literature review. Pediatr Rheumatol Online J. 2021, 19:103. 10.1186\/s12969-021-00595-1","journal-title":"Pediatr Rheumatol Online J"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.27839","article-title":"Clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease diagnosed in a patient on extracorporeal membrane oxygenation","volume":"14","author":"Al-Husayni F","year":"2022","unstructured":"Al-Husayni F, Munshi A, Qanash S, Shaikhain TA, Alzahrani Z, Alghamdi B. Clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease diagnosed in a patient on extracorporeal membrane oxygenation. Cureus. 2022, 14:e27839. 10.7759\/cureus.27839","journal-title":"Cureus"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.46497\/ArchRheumatol.2022.8719","article-title":"Spontaneous pneumomediastinum and cutaneous ulcers complicated in a patient with dermatomyositis and interstitial lung disease","volume":"37","author":"Kwon M","year":"2022","unstructured":"Kwon M. Spontaneous pneumomediastinum and cutaneous ulcers complicated in a patient with dermatomyositis and interstitial lung disease. Arch Rheumatol. 2022, 37:136-8. 10.46497\/ArchRheumatol.2022.8719","journal-title":"Arch Rheumatol"},{"key":"ref35","article-title":"Spontaneous pneumomediastinum, a rare manifestation of clinically amyopathic dermatomyositis","volume":"1","author":"Rocha ML","year":"2022","unstructured":"Rocha ML, Gago L, Sepriano A, et al.. Spontaneous pneumomediastinum, a rare manifestation of clinically amyopathic dermatomyositis. ARP Rheumatol. 2022, 1:251-4.","journal-title":"ARP Rheumatol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.4322\/acr.2024.511","article-title":"Anti MDA-5 associated rapidly progressive interstitial lung disease complicated by viral pneumonia - a fatal outcome","volume":"14","author":"Mitra S","year":"2024","unstructured":"Mitra S, Parvathy N, Garg M, Devkota S, Bansal S, Sehgal IS, Gupta K. Anti MDA-5 associated rapidly progressive interstitial lung disease complicated by viral pneumonia - a fatal outcome. Autops Case Rep. 2024, 14:e2024511. 10.4322\/acr.2024.511","journal-title":"Autops Case Rep"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1155\/crrh\/2017703","article-title":"Subcutaneous emphysema and severe interstitial lung disease in the setting of anti-MDA 5 positive dermatomyositis in a Hispanic patient","volume":"2025","author":"Subhadarshani S","year":"2025","unstructured":"Subhadarshani S, Woodie B, Bookal E, Reed J. Subcutaneous emphysema and severe interstitial lung disease in the setting of anti-MDA 5 positive dermatomyositis in a Hispanic patient. Case Rep Rheumatol. 2025, 2025:2017703. 10.1155\/crrh\/2017703","journal-title":"Case Rep Rheumatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/388921-anti-melanoma-differentiation-associated-gene-5-dermatomyositis-with-rapidly-progressive-interstitial-lung-disease-complicated-by-pneumothorax-pneumomediastinum-and-subcutaneous-emphysema-clinical-course-compared-with-reported-cases-worldwide","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T02:33:06Z","timestamp":1755570786000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/388921-anti-melanoma-differentiation-associated-gene-5-dermatomyositis-with-rapidly-progressive-interstitial-lung-disease-complicated-by-pneumothorax-pneumomediastinum-and-subcutaneous-emphysema-clinical-course-compared-with-reported-cases-worldwide"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,18]]},"references-count":37,"URL":"https:\/\/doi.org\/10.7759\/cureus.90433","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,8,18]]}}}